RVMD - Earnings call transcript Q3 2024 | Revolution Medicines, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to Revolution Medicine's Q3 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Ryan Asay, Senior Vice President of Corporate Affairs. Please go ahead.

Ryan Asay

Thank you and welcome, everyone, to the third quarter 2024 earnings call.

call today's on me are Dr. Joining Revolution Goldsmith, Medicine's Chairman Dr. Officer; Executive Chief and Mark President and of Chief our Kelsey, Steve R&D; Financial Jack Officer. our Anders, Dr. for be today's and many Wei Q&A statements inform future we our Chief events this Officer, are such certain join Lin, risks call statements during will with Medical you that to portion because and would call. I us of make like forward-looking uncertainties. to subject will the deal statements. from materially those differ may forward-looking the results Actual in

recent a available these Form release review The and Medicines' Form our For of Goldsmith, Exchange our and corporate afternoon Chairman the released section annual I'll with our of on Commission. please Mark Chief discussion and quarter uncertainties, updates. and we in filed Mark? at financial Investors over full Executive risks ended is report revmed.com. With that, call U.S. Revolution are report XX-K and website turn XX, press XX-Q the Dr. results Securities This the September to for on XXXX Officer. that quarterly the

Mark Goldsmith

living inhibitors one The RMC-XXXX one on adenocarcinoma, our RAS(ON) RMC-XXXX, strategic priority provided pivotal in We some our advance in been to road non-small delivery has patients difficult believe with meaningful RAS(ON) of into cancer. that pancreatic lung inhibitors and of focused to our which ductal able medicines. Thanks, to RAS-addicted priorities in year, good development we for for inhibitor, we the through with as first Revolution the development multi-selective have of that to pioneering revolutionizing RMC-XXXX, be are highest of targeted XXXX and PDAC refer been with clinical cell It's has you treatment patients At treat portfolio provide to this for first-in-class development: cancers increasingly impact RAS(ON) discovery, its start we to the trials, Medicines, a demonstrate of Ryan. innovative the we the cancers. At to and most afternoon. RMC-XXXX. potential X committed map

second of lines aimed therapy, the begin to Our into earlier PDAC. particularly the in path reach to of defining priority expanding RMC-XXXX

priority RAS(ON) and inhibitor our development. qualify selective RMC-XXXX, for selective a to RMC-XXXX, third mutant-selective a RAS(ON) GXXD inhibitor late-stage GXXC Our aimed inhibitors

have against we priorities. We specifically progression-free our and first compelling in randomized treatment Based PDAC with Last study. We in month patients RMC-XXXX durability Phase previously a demonstrated treated safety, made we survival results, PDAC. GXXD tolerability in are progress and activity with anti-tumor on this second-line metastatic patients cohort of treated substantial these shared metastatic dosing in actively and with study PDAC data, encouraging with survival overall patients III these of RMC-XXXX. global now initiated KRAS patients with

new RMC-XXXX exploring combinations across to tumor RMC-XXXX come. our inform advance studies future pipeline design lines there types including extend continue and and by PDAC of We to to more And cell is lung therapy pivotal multiple and non-small cancer. including earlier the in and of

portfolio inhibitor to of hand number summarize RAS(ON) we both a cancer, Q&A. our the PDAC call at open a few and we overview studies CFO, to He'll from Dr. results then who the provide as cell remarks a shared Symposium, I call a in lung several non-small combinations. I'd quarter Steve? Meeting. including commonly our cancer. EORTC-NCI-AACR of closing summary Jack referred Kelsey, across when We the results disclosure have over our Steve Triple this to cell we're to of updates Anders, before the the quarter to the will lung also RMC-XXXX of and third like the RMC-XXXX non-small look provide monotherapy financial recently brief will plans ahead share and forward sharing in now approaches President taking milestones monotherapy our including R&D,

Stephen Kelsey

updated Thanks, Triple and RAS(ON) inhibitors data on study. PDAC, in Mark. had two opportunity activity RMC-XXXX antitumor overall including present we October, survival safety initial and our study to in of our At survival the our monotherapy monotherapy from progression-free RMC-XXXX and recent Meeting the from

standard progression-free XX% survival, at perspective is on in therapy I most have Before by patients of all believe this first-line need States in current results, PDAC. median months. We care to than cases I X relating is would months or for More of than every is published results alone, cancer. patients, RAS mutation common clinical the X.X like who XX,XXX are majority indicate cancer pancreatic on X of driven outcomes review is PFS, RAS for mutations, to treatment more approximately Based metastatic GXXX. GXXD these provide R&D Chemotherapy RevMed's stage. the with and into United are found median these diagnosed pancreatic some a patients trials, with disease. improved half devastating these in survival overall the approach to progressed cases the of single being XX% Over the second-line diagnosed for for being patients. X to year

Events details oral first-line oral reported RMC-XXXX. on The approximately diagnosis presented and months multi-selective summary median RMC-XXXX. X provide RAS(ON) for patients PFS do RMC-XXXX website found of corporate Presentations of OS of median for improvement. I of will combination RAS(ON) our now inhibitor chemotherapy be recently a GXXD at can still brief PDAC the at the room XX of treated initial our and selective with leave with approximately revmed.com. Beginning metastatic While page better, results inhibitor months the and our

XXrd months. we the and metastatic PDAC daily received had of monotherapy of As the who achieved months report received XXX with median chemotherapy now of XX.X as of data to patients GXXX of that prior OS a milligrams dose regimen of matured for X.X XXX XXXX, mutations levels who one across RMC-XXXX have a median and cutoff can PFS a with data July, the

maturation who This to registrational have in and dose in second-line patient data and median the clinical the was OS is For our of months profile robustness in line patients for optimism therapy pancreatic mutant increasing dose highest about at study justify III was was announcing encouraging tolerability PDAC this This of metastatic X.X patients response highlighted and the the data. and patients overall dosed reflecting average all received doses, these study. these doses safety release second-line the in milligrams these as patients At is GXXX with setting actively for one levels, at median first the XX.X of manageable was XXX, XXX was month's also Phase prior intensity dose tumors months. RAS RMC-XXXX of the profile recruiting including continue clearly press of study last the these XX%. The RASolute our daily, PFS with cancer. XX%, rate

presented month patients last Phase RMC-XXXX, to GXXD Moving focus inhibitor, with our from the at the with the data Triple monotherapy clinical initial selective PDAC. I main study on of RAS(ON) Meeting we a RMC-XXXX

adverse RMC-XXXX XX% treated September cutoff data encouraging disease antitumor date, for reported daily, X, which control level the rate clinical recommended candidate treatment-related Grade of well XXXX, is tolerated XXX activity. We patients. with event dose with X II objective adverse X,XXX As milligrams patients and XX% demonstrated a amongst predominantly preliminary the rate an response Phase at was low-grade reported dose. and One was manageable events. RMC-XXXX this

take disclosures Based the profile and share exploratory patients represented well I'd and the mature RAS(ON) the the we share updated clearly our to RMC-XXXX, of inhibitor. well We forward early, response overall like durability continues sharing remaining overall for on several are overview pancreatic important it subset KRAS to as for the We experience data activity will survival. The work inhibitor to by XXXX time plan strategic evaluation. Ultimately, GXXC part to survival tumors the our read anticipate brief to RMC-XXXX, RAS(ON) potential progression-free both including of XXXX the monotherapy cancer. look The as remaining will the RMC-XXXX antitumor the is our of to pembrolizumab more lung development also RAS we rate and more data defined of initial with PDAC, activity initial RMC-XXXX genetically and RMC-XXXX upcoming a provide the in selective plus committed in as disclosures and for from PDAC a and the harboring currently RMC-XXXX cancer true non-small remain RMC-XXXX relevant optionality doublet data our clinical on doublet an data activity measures with tolerability non-small safety be undergoing RMC-XXXX these that fully antitumor sufficiently both RMC-XXXX data as cell from for the studies in with encouraging. RMC-XXXX. is While are plus the gears, patients. Switching in combination for characterize when of quarter, lung important and GXXD hope cancer with consistent outcome data agents combinations, profile us options which RMC-XXXX, in RMC-XXXX priority provide combination with which us. of including largest of RAS(ON) of GXXD, of RMC-XXXX encouraging number fourth use as the cell initial

III reach with the treated evaluating RMC-XXXX and Phase initiate of in alignment in quarter to first registrational lung non-small previously a mutant monotherapy study expect RAS XXXX. patients We as regulatory advanced cell cancer

turn Jack to the like provide Anders, a over to CFO, our call Jack? financial I'd update. Now to

Jack Anders

on the ended plan. cash project billion our planned operations quarter we $X.XX investments, with of We can fund Steve. operating third based Thanks, XXXX and which XXXX in into current

expense. G&A net due and for of G&A with preparation clinical was compensation compared for compared additional XXXX. The to was quarter XXXX inhibitors, with for third due increases million of of The of increase additional compensation personnel-related million the million stock-based expenses increases expenses stock-based Turning million wave first higher third to primarily expenses the expenses in to expenses. The the to million for $XXX.X $XX.X headcount headcount, increase was associated R&D in million associated to expenses third commercial activities our $XXX.X of $XXX.X XXXX. quarter and the for XXXX. in for the expenses expenses, expenses compared of loss increase for third quarter due in to operating personnel-related quarter $XXX.X trial-related quarter in expense. Net XXXX XXXX R&D were were the $XX.X RAS(ON) quarter loss was to primarily of third third

We million financial million. That expect estimated Mark. to expense and XXXX are the $XXX noncash full year stock-based includes $XX update. projected $XXX reiterating compensation which the to be net turn now and between concludes our million, over call million back between continue guidance GAAP $XX and I'll of financial loss to XXXX

Mark Goldsmith

across recent Triple Jack. intensity have programs are with impact so both RMC-XXXX and advancing we to outcomes make the Based and you, The with continues the to opportunities compelling Revolution on underscore patients we portfolio. for RMC-XXXX presentations far, PDAC. substantial Thank Medicines among progress Meeting our profiles demonstrated meaningfully speed.

development Phase position These monotherapy for III believe potential setting. we patients profiles, into for PDAC. about based be paradigm the to PFS results in an RMC-XXXX for it strategy, care to if initial for combinations. Nonetheless, recognize clinical global, important validation milestone data move place our optimal the provide treated acceptable on in data PDAC mature with Steve encouraging. the engine very previously approach therapy understanding PDAC new in compounds that innovation RMC-XXXX also us also evaluation OS that ongoing RMC-XXXX patients profile, potential controlled of including emerging RAS(ON) become our a study, portfolio proof-of-concept in RMC-XXXX As portfolio there the inhibitor reproduced optimism the and in We the well the data clarity this representing of very targeted a to shared, our as with take PDAC should and standard both are for could is their time safety for randomized, Revolution differentiated and pleased from in the sufficiently potential significant will setting. The organization. frontline a We're an to support Medicines third achieve

the platform has oncology amino at compelling has in and profiles. include a achievement. for covalent in These irreversibly X delivered an selectivity; X RAS(ON) RAS(ON) charted X work oral extraordinary RAS(ON) Our inhibitors targeting stage engages protein new a inhibitor distinct position for aspartic RAS, selectively investigational X BRET; state, X non-covalent drugs oncogenic clinical designed tri-complex inhibitors inhibitor and This in that and investigational mutation territory chemistry-first with inhibitor; X designed by covalently, acid aberrant RAS(ON) knowledge, and to drug. our clinical XX acid X RAS(ON)

in first In III Phase wave making improve highlights clinical the and in treatment significant it and step inhibitor an efforts the in evolution preclinical cancers. Importantly, RAS(ON) are study of of continue successfully significant space. with priorities discovery with first and cancer conclusion, for translatability RAS-addicted obtained clinical patients mission patients us revolutionizing the our data is to progress to driving strength encourages the progress registrational the and with programs be we've cancers. Initiating milestone of laying outcomes many RAS-addicted our cancers. foundation long-term, the this we our progress this goal of for our XXXX key important supporting on clinical sustainable with and for of RAS-addicted in first in our patients anticipate second-line a will company's studies We pancreatic executing

possible. This and and cancers. I'd look patients you an And thank like well non-small cell recognize high we monotherapy to support, and these be today. with the forward efforts progress collaborators, studies for RevMed pipeline scientific the Our remain investigators, our advance call to operator update moment session. And I Q&A Without clinical lung caregivers, now are cancer the take a the for remarks this continue and to to made employees tireless to our over need business unmet we've will to the us of behalf of patients. sharing and we concludes wouldn't commitment enabling and capitalized, ongoing shareholders on combination quarter. in prepared their the and advisors and turn

Operator

first question Peter from Our Barclays. Instructions] Lawson comes with [Operator

Peter Lawson

with I what should the months around thinking of in we and months be Great. over how GXXC effect between any the one next that of the and combination multi versus efficacy the we would get few pembro the for profiles datasets just signals? and looking kind X we combinations be about terms of should combination first in those the side to the terms then in guess be

Mark Goldsmith

Well, there is a is and think pembro question. the studies to issue. RAS(ON) was seen signal the signal are primarily The difference study. is the we appreciate the doublet I that hepatotoxicity they study. a And want most clear inhibitor that I important the Peter. you, between pembro Thank inhibitors. We zeroed the are with generation that RAS(OFF) on study first in GXXC safety

to the considered to mentioned recently combination a months any ago at really of had XX pembrolizumab times if was a come problem, RMC-XXXX off of that risk those there significant did patients data have were number As hepatotoxicity. evidence for and show did we've we referred in about actually patients past, reported started of and be hepatotoxicity, not who high

But So us preview. X underway what that gives some the primarily is looking for. And have we compounds. we're level of administration of that's concurrent now what

for we'll Obviously, and saw needing have that that that that think, from we those. the people. And on can to agents issue closer that's the about it monotherapy see X to we tolerability, just I point, plus today don't there combination, we're that to looking tell about best you evidence that distinguished to RMC-XXXX that even here activity translates I XXXX itself preclinical open. the qualitatively But leave from some less those getting clear. in into models something the qualitative studies. we're really And outstripped the that that have disclosing With focused particular because which sort really a the we we characteristics, the in of anticipate we're we saw, profile combination

Operator

comes with Guggenheim Schmidt from Michael Our next Securities. question

Michael Schmidt

what pushed slightly III you I covalent cancer. on are that of before... GXXC of inhibitor that background, planned patient with some histologies are treatment the a FDA And follow-up Phase comment have you know could to align about on the just cancer sort population is included lung inhibitor? And prior what items that question well? a with in then that the patient us study, you there Can out. of the as you Just or exclusively just patients combination, study doublet lung in other RAS(ON) to the the timing remind on

Mark Goldsmith

What Is part the bit you were out end your Phase timing. at the but of faded the there, second cancer think timing the the a I lung III little that about asking trial? drove of Sort question? of

Michael Schmidt

with some that that What you still FDA front? the to of Yes. things need are with on align the

Mark Goldsmith

Yes.

reality, Phase a to the transparent KRAS-GXXC-bearing So deliberations trial, want trial on of are this become activities, details point III mixture the it registrational launching out, that on study provide the our the on near that tumors. to an the to the really be this future. want of to be see cancer study. Steve December of too out speaking, the to a And that these on we And committed were cancer the with lung these and which that we it'll for just able RASolute the and about data. And the lot obtain the trial. XXX the much lung pointed remain also lung first with treatment that before III It's of a of Phase it's tumor regard eligibility. stretch in around about call it's Phase program mixture recognized we trial the the on cancer we expect, analysis fully path having pancreatic We end too a prior all the launch patients assume bit updated the can't top types, it's we we apparently Obviously, when regulatory the just understood of solid to our complete I make clear you a could But accelerate timing wanted in holiday we to optimistic a as simply corner, backgrounds. year question, to I to and cancer critical of and to initiate dataset best practically internal alignment quarter. But it. I share initiation. study about of detail that, were with do

to able move can't this hard certainly any me continue We to do today. second achieve detail liftoff soon pivotal as as forward, emphasize let more just practical. Again, trial be provide to on pushing expect will we but

promised this to stay the everybody quarter. data for disclosure ask Just tuned

Operator

Oppenheimer. from comes Jay question next Olson Our with

Jay Olson

the on with evaluating progress. of Therapeutics you there a clinical you're focusing the some on? XXXX have and color clinical collaboration Since indications PRMTX and that their Congrats the on development inhibitor, can strategy Tango XXXX with combination you provide all

Mark Goldsmith

Unfortunately, other with different to information happy these Tango, deletion. who Jay. any to done than be we're addresses those Thanks, really supply and that no, each really will provide drug X who component providing RAS preclinical We're but signaling studies. more be contributing participating, may more we MTAP obviously that some we to in sponsor oncogenesis both combination, patients can't than work a agents that give what you Tango can't information reported. the We mutation clinical have have of

certainly both And to signaling preclinical it that try so results sense And makes regard. the those to in suppress of were contributors. encouraging

we're excited to So be help able to study. the support combination

Operator

Our next question Cowen. Marc TD Frahm with comes from

Marc Frahm

just you about start Just just following for initial of Phase seems decision to and question, year a was trial that have that up kind explain from so pancreatic the you why forward to the ago, kind of on you kind Michael's parallel. still out you decision lung, to X? Can kind intended diverged you put move answer of how for -- timelines made like a of of earlier year statement how questions in differed kind and what actually to it needed ago the starting seem the that -- the to IIIs made

Mark Goldsmith

we really through we to those to they just steps I And to the that. a there's to able very will don't differ. It's I for exactly to mean, get be go think much think same. don't that a enrollment what really than year that. essentially much It's can hard I be color are have can ago phases start to the more there's able reality. provide practical a predict study.

Marc Frahm

maybe not combinations then or just these of about is kind are novel strategy kind but you much forward Should more of XXXX? of with that we types more of through moving the approaching with talk collaboration these or so see your one-off? itself, lot just a Tango deals of how this Okay. And novel, collaborations a

Mark Goldsmith

to be I it's going doubt a one-off.

do almost long things the do we'll reviewing terms agents, a other us have requests collaborative I be of It collaboration, accommodation will expect which with for overwhelms other just studies. for for -- of in targets, list. other list We so But there RMC-XXXX.

we We're multiplex RMC-XXXX course, other combining we feel combining what Of chemotherapy are. to as do those with pembrolizumab. and RAS(ON) studies. priority you RMC-XXXX various And the combining we combinations with combinations, that need prioritized studies of with those. inhibitors. know RMC-XXXX We're We're

but combination other time. priorities, expect near-term our will be I over are will those studies So do there that emerge

Operator

comes Our Stranahan of with next from Bank question America. Alec

Alec Stranahan

to should liquid Curious you'd the data, ASH. ahead that proceed we and the looking AML or expect what color on to to And studies in seems to and thoughts maybe options around Just the fedratinib at see the setting considered being of maybe hear application based platform preclinical your any RAS(ON) the some clinical like to around want to venetoclax here. abstract? combinations tumors

Mark Goldsmith

of be forwards. to be outsourced they're to and Alec, now hematology presenting the be component and collaborators been meetings that has true, To at our the data almost up going ones ASH program going other academic completely will to

that like therapies on West priority the us targeted set distant future. relatively We medium-sized point at of of through We on not But infrequent opportunity for carry by there focused inhibitors mechanisms the really very appreciate colorectal that United much medical the any mutation. and have collaborators more the is mechanistic the for is of RAS acquisition it that been biotech not like top by the an development pancreatic in a from academic escapes lung that AML. We of not mutations need. we so one increasing, basis development the as that had which cancer clear unmet have major now, Coast do done in course, being RAS might a becomes of AML cancer us. States, clinical some to clinical work the tumors it's the that's cancer, non-small cell plan FLTX for up company And and appreciate right some do too

Operator

comes Partners. Our from Leerink next with question Jonathan Chang

Jonathan Chang

your different runway ways can and what's color cash pancreatic could runway what's pipeline? across Specifically, guidance? in some lung me. of the you into baked for the proceed one guidance, you cancer cancer on provide Just baked terms in, On in

Mark Goldsmith

Jonathan. Thanks,

that. I on Jack comment think can

Jack Anders

disclosed what's to X we've we is the studies With in moving cash baked there second-line Phase III are that guidance, the ahead Yes. with. that regards

adjusted that, Beyond the costs a model use adjusted probability multitude potential we additional regards a and that of there programs trials. But model. opportunities and to in with is push forward use we we probability each -- pivotal

cash can't we forecast. what So don't really in we Phase describe are But programs trials. baked runway there the those fully -- what's additional specifically in III are second-line X

Operator

[Operator JPMorgan. Eric Instructions] Our Joseph question comes with next from

Eric Joseph

Just on to with chemotherapy. that the I work of think to combination potentially XXXX, triplet the non-small combinations regimen XXXX and you if looking curious strategic you're frontline I'm look at cancer? pembro triplets, about of pembrolizumab, of opportunities also know as guess expand how do cell you in utility lung in

Mark Goldsmith

Wei, on that? you comment want to

Wei Lin

Yes.

a you the it's Within That what XXXX actually quadruplet our really as plus small the pembro platinum-doublet cell. referred chemotherapy. to into of plus go study, triplet,

dose doing clearing of after we're rapid actually plus So on. and identifying for the pembro XXXX with sequentially the appropriate initiate it and chemotherapy the doublet we'll combination

will be ]. So [ valuable ultimately both

Eric Joseph

but keeping OpEx just the And just -- year keep mind. part here significant of thinking jump I whether past intact. just spend the should the you're in side, I'm on with onetime there's into wondering spend? sequential sort how any items, quarter, pretty guess, you should And items ramp it. Got from XXXX nonrecurring full this we about of early be the Okay. guidance in

Jack Anders

as out onetime to within or in onetime within items. we've regards with So the potential what XXXX, historical that onetime stands results reported items items nothing to-date

are look we XXXX kind for where a year-to-date. at guidance take If and of look our at midpoint you the of

a our are $XXX from guided any in to a and QX XXXX, is -- midpoint with of that probably $XXX about a perspective. And bit likely guidance ramp will assumes net net guidance we year-to-date So haven't million do loss we little that in specific million, into future. loss so regards to going we our the of the

started to Obviously, and I we expenses starting that to are plan think Phase going our up. plan we However, one Phase that X another. we go trial III starting on assume on III it's fair --

least that preparing And pivotal a a opportunities that we've the from from at have We X of are those -- commercial launching. to out going building perspective. said organization, outside also launch a of lot be we're kind trials we of

XXXX outside to guidance no specific So increase. of expect expenses do we

Operator

with comes from Laura next question Prendergast Our James. Raymond

Laura Prendergast

A at proof-of-concept increases you quick last Nature comments internally any question looking was GXXX paper this this, about and in of have how just that GCPA RAS regarding XXXX out published on also that ]. general? combinations actually potential or just generally in Is that showed you're effectivity that MSK week guys regards a thinking the [ been especially mechanism to

Mark Goldsmith

it at of Laura. fact Thanks, Yes. Yes, we and additional some and it mechanism we're years in course, time discovered NCI first we very few ago of scientific aware a ago. this disclosed ourselves an RAS conference

RAS(ON) have quite interesting. It lower index of it. with level normal signaling. We therapeutic yes, we're in in RAS(ON) with a signaling cells So by contribute familiar the fact it's quite affecting of up-regulated to more RMC-XXXX that than think may RAS signaling in cancer cells

it. to to the happy were think likely We So is sure foundation contributor the and RMC-XXXX. be to work for were with it we it. And for lay we familiar helped see a

Operator

from Merle next Our with question Ellie UBS. comes

Unknown Analyst

translate thinking I ] on potentially looking wait you you where that as PDAC, timing, terms in for first-line III just Phase what [ would is first potential about second could guess, then you're in I of a guess data more to mechanistically, the setting? into to into driver earlier and like the just or first related we how expect this line line efficacy this in see and and or study would be guess, be are Ellie. It's line here? different I something potential less could Sam strategies kind for for this And of a moving parallel? And of the studies run being graphic like line second we potentially might

Mark Goldsmith

Thank Okay. the you questions. for

X there in questions were of remember them. X think there think I I and I

second have remember we helping before to do sorted the we I to various -- one get Phase have what can most regimen regimen that. study? the a determine going That are study into talk be one. III study there? launching easiest going design that us the what little waiting Wei out, going line line and up in about results sets and are to one's line soon on, think first have we Maybe I study we'll the that No, overall we we as to that from us in So the include things might optimized bit a how is as we first what's trial for move the that

Wei Lin

Okay. Yes, happy to answer that.

believe the as mind our we the think I the setting. agent in exceeding the now first-line of in a second right benchmark line or PFS, the with monotherapy this established data So OS first-line active the being proof-of-concept

-- forward in So we the potential review-based agent that one as as monotherapy single with that be a developing Phase well eagerly actively also includes of additional planning are III treatment [indiscernible] can potentially regimen. enabled investigation as expandable with Phase arms And therapy arms. We're so III regimen gemcitabine-based for I a think combination moving with trial. those in registrational standard-of-care arms, as

that's way kind thinking of So the the about first-line phase. we're

think correctly. on, rephrase let know question, expanding I I think your address if to I it me I'm going it. Please

or I efficacy therapy, not. ask RAS driver across believe whether changes different that whether we potentially could or of and do change is, that think trying a to what the is you're lines not

second-line been to first do pressure Therefore, RAS a all. sensitivity proof-of-concept do number a line. across that a same providing because be and think, therapy, one, any of of the at the selective or believe to lines believe should is selective then has without regardless line of the translate I think resistance there in the with therapy I remain -- RAS pressure fundamental to we we driver not inhibitor line able

I there's the active validating treatment between line, terms among that think in And risk PFS We in plus XX% have comparison a line. which concept than in right? So shown second progression second-line we actually effect measure concept. data, scientific have greater more patients And in ratio, either for that it's we're demonstrate and and of line than reduction hazard line. in proportionally, data third-line third therapy, also target third that shown so really built double we've also and in this by that third the of

a meaning applying of basic reduction that can to hope of if risk treatment concept similar line first as progression or line for greater. first we in then So well, that we XX% expect effect holds,

are the of thinking. our kind current those So

Operator

Kelly from Jefferies. comes question final with Shi Our

Unknown Analyst

] This on Kelly. is [ Clara for

quick just can you PRMTX reason if programs? partner the on among on the choice of add other question color collaboration. any for Tango's clinical clinical So collaboration a follow-up Wondering

Mark Goldsmith

Yes.

Tango's asking compound, an We've but preclinical of some choice certainly Tango's and they've Sure. done mentioned our about It the in like Tango done compound. some of choice, work our choice earlier field. looks as with with work There I you're the our compounds. us, not compound. other compounds So preclinical are interesting

collaboration looks like inhibitor. have But some doesn't So into do we with model preclinical combination in that we that that study what systems. wouldn't mean a visibility another PRMTX

in early combination We happy us trying partners be to we're best are the many do it's different make many to actively we'll But any and combination for different too to mentioned of, it's for the disease I And with about far collaboration. studies RMC-XXXX agents as find declarations targets. earlier, that. one across probably

Operator

now would Mark at Goldsmith, questions this and to further to Chairman remarks. Chief it like for no back I Officer showing turn time. closing Executive am I

Mark Goldsmith

Thank you, continued for everyone Medicines. Revolution thank participating And support your today to you and of for operator.

Operator

your you Thank the today's participation conclude conference. for does in This program.

disconnect. now may You

Revolution Medicines (RVMD) 6 Nov 242024 Q3 Earnings call transcript